DFE Pharma has announced the launch of a new product in its range of Lactohale inhalation grade lactose products; Lactohale 400 milled anhydrous lactose is described as a grade for formulations “where a relatively good flow with some cohesiveness is required.” According to the company, the median particle size of Lactohale 400 is 100μm, and DFE Pharma will work with formulators to customize the product as needed for a particular application.
DFE Pharma CEO Martti Hedman commented, “As co-developers of dry powder inhalation (DPI), DFE Pharma has a long heritage and great expertise in excipients for inhalation, while we continuously innovate in new premium solutions for inhaled therapies,. With Lactohale 400, DFE Pharma expands its comprehensive lactose-based portfolio, designed to offer optimized excipients to match the increasing range of inhalant devices, each with different performance characteristics.”
Read the DFE Pharma press release.
